AstraZeneca Pharma India Ltd to launch Sodium Zirconium Cyclosilicate powder in Nov 2025

AstraZeneca Pharma India Limited will launch Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) in November 2025 in India.

Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) is indicated for the treatment of hyperkalaemia in adult patients.

The company received the receipt of Import and Marketing Permission in Form CT-20 from the Drugs Controller General of India in March 2025 for Sodium Zirconium Cyclosilicate powder for oral suspension 5 g and 10 g (Lokelma).

Shares of AstraZeneca Pharma India Limited was last trading in BSE at Rs. 9177.80 as compared to the previous close of Rs. 9140.25. The total number of shares traded during the day was 730 in over 253 trades.

The stock hit an intraday high of Rs. 9220.50 and intraday low of 9061.00. The net turnover during the day was Rs. 6652527.00.

Source : Equity Bulls

Keywords

AstraZenecaPharmaIndia INE203A01020 Pharmaceuticals SodiumZirconiumCyclsilicatePowder OralSuspension November2025 IndiaLaunch